JSE-listed Aspen Pharmacare will adjust production schedules at its manufacturing plants to ensure supplies of critical medicines, such as antibiotics, should SA’s Covid-19 outbreak trigger a sudden increase in demand, according to CEO Stephen Saad.

There is no vaccine or cure for the coronavirus that causes Covid-19, but there could well be a surge in demand for products such as antibiotics to treat secondary infections, he said. Aspen has also given the government an undertaking that it will alter its production plans to ensure continued supplies of other critical drugs, including those used for chronic conditions, should the need arise, he said...

Subscribe now to unlock this article.

Support BusinessLIVE’s award-winning journalism for R129 per month (digital access only).

There’s never been a more important time to support independent journalism in SA. Our subscription packages now offer an ad-free experience for readers.

Cancel anytime.

Would you like to comment on this article?
Sign up (it's quick and free) or sign in now.

Speech Bubbles

Please read our Comment Policy before commenting.